NCT06825845View on ClinicalTrials.gov

Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy

Not yet recruitingOBSERVATIONAL
Enrollment

1,500

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

December 31, 2039

Study Completion Date

June 30, 2040

Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
DRUG

Zevorcabtagene Autoleucel

Non-intervention

Sponsors
All Listed Sponsors
lead

CARsgen Therapeutics Co., Ltd.

INDUSTRY